A Randomized, Double-blind, Multicenter, Placebo-controlled Study of Adjunctive Aticaprant Plus an Antidepressant for Relapse Prevention in Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-511057-22-00

Acronym

67953964MDD3005

Enrollment

339

Registered

2024-11-18

Start date

2024-12-04

Completion date

2025-02-28

Last updated

2024-12-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Major Depressive Disorder (MDD) with Moderate-to-severe Anhedonia

Brief summary

Time from randomization into the DB treatment maintenance phase to the first documentation of a relapse event

Interventions

DRUGMatching placebo tablet

DRUGJNJ-67953964

Eligibility

Sex/Gender

All

Age

18 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
Time from randomization into the DB treatment maintenance phase to the first documentation of a relapse event	—

Countries

Belgium, Bulgaria, Czechia, France, Germany, Greece, Poland, Romania, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026